Theranexus announced the initial results of their Phase I/II clinical trial for juvenile Batten disease (CLN3). After a 9-week course of Batten-1 with the maximum dose of 600 mg/day, the first results of the Phase I/II trial enrolling six patients with juvenile Batten disease (CLN3) aged 17 and over showed good patient safety and tolerability, and a pharmacokinetic profile in line with expectations.